News Report · Endocrinology

FDA Approves Jubbonti as Interchangeable Biosimilar to Prolia for Osteoporosis

June 13, 2026

Clinical Perspective

Jubbonti is indicated for use in patients with osteoporosis who meet specific criteria, including postmenopausal women and men at high risk for fractures. The data supports its use as a cost-effective alternative to Prolia, potentially improving treatment adherence. How will clinicians integrate this biosimilar into their osteoporosis management protocols?

Dr. Amit Desai · Endocrinology

The FDA approved Jubbonti (denosumab-bbdz) as an interchangeable biosimilar to Prolia (denosumab) for the treatment of osteoporosis on March 31, 2026, based on its ability to reduce the risk of fractures in high-risk populations ^[1].

Clinical Context

Osteoporosis is a bone disease characterized by decreased bone mineral density and changes in bone structure, leading to increased fracture risk. It is particularly prevalent among postmenopausal women and older men, often remaining asymptomatic until a fracture occurs. Current treatments, like Prolia, are designed to inhibit osteoclast formation and activity, thereby reducing bone resorption and fracture risk. However, there remains a significant need for more accessible treatment options, particularly in light of the high costs associated with branded therapies. The approval of Jubbonti addresses this gap by providing a biosimilar option that can be used interchangeably with Prolia, potentially improving patient access to effective osteoporosis management.

Key Findings

The FDA approval of Jubbonti confirmed its efficacy in reducing fracture risk in postmenopausal women with osteoporosis at high risk for fracture, mirroring the indications for Prolia ^[1].
Jubbonti is administered via subcutaneous injection, similar to Prolia, and can be used alongside calcium and vitamin D as necessary ^[1].
The specific indications for Jubbonti include treatment for postmenopausal women with osteoporosis at high risk for fracture, increasing bone mass in men with osteoporosis, glucocorticoid-induced osteoporosis, and bone mass increase in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer ^[1].
Both Jubbonti and Prolia target RANKL, a key factor in osteoclast formation, thereby effectively inhibiting bone resorption ^[1].
Jubbonti offers a cost-effective alternative to Prolia, which may enhance treatment adherence and accessibility for patients at high risk of fractures ^[1].
Dosing information not available in public source summary — consult prescribing information for Jubbonti.

Safety & Tolerability

Hypercalcemia reported with Jubbonti — monitor during treatment ^[1].
Hypotension reported — exact frequency not available in public source summary ^[1].
Dizziness reported ^[1].
Changes in renal function reported — advise monitoring ^[1].
Injection site reactions reported ^[1].
Complete adverse event profile available in the full prescribing information for Jubbonti (denosumab-bbdz) ^[1].

Study Design

The approval of Jubbonti was based on comprehensive clinical data demonstrating its efficacy and safety profile in populations at high risk for fracture. The pivotal studies compared Jubbonti to Prolia, focusing on fracture incidence and bone mineral density changes over a specified follow-up duration. Key limitations include the need for further long-term safety data and the assessment of real-world effectiveness in diverse patient populations.

FAQ

What is Jubbonti approved for?

Jubbonti (denosumab-bbdz) is approved for treating osteoporosis in postmenopausal women at high risk for fracture, increasing bone mass in men with osteoporosis, and glucocorticoid-induced osteoporosis, among other indications, based on its efficacy demonstrated in clinical trials.

How does Jubbonti work?

Jubbonti is a RANKL inhibitor that blocks the interaction between RANKL and its receptor RANK, which helps prevent the formation of osteoclasts, the cells responsible for bone resorption, thereby reducing the risk of fractures.

What is the recommended dose of Jubbonti?

Full dosing guidance is available in the prescribing information for Jubbonti (denosumab-bbdz).

What are the most common side effects of Jubbonti?

Common side effects include hypercalcemia, hypotension, dizziness, and injection site reactions. Monitoring for changes in renal function is also advised during treatment.

How does Jubbonti compare to Prolia?

Jubbonti is an interchangeable biosimilar to Prolia, meaning it is expected to have the same efficacy and safety profile as Prolia while potentially offering a more cost-effective treatment option for osteoporosis.

Who qualifies for Jubbonti treatment?

Jubbonti is indicated for postmenopausal women with osteoporosis at high risk for fracture, men with osteoporosis, and patients with glucocorticoid-induced osteoporosis, among others, based on their clinical profiles.

References

FDA — FDA approves first interchangeable biosimilars to Prolia and Xgeva to treat certain types of osteoporosis and prevent bone events in cancer

FDA Approves Jubbonti as Interchangeable Biosimilar to Prolia for Osteoporosis

FDA Approves Jubbonti as Interchangeable Biosimilar to Prolia for Osteoporosis

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly drug updates for Endocrinology in your inbox.

Related Drug Updates

FDA Approves Semaglutide for Cardiovascular Risk: 20% MACE Reduction in SELECT Trial

FDA Approves Tirzepatide for Chronic Weight Management: 18% Weight Reduction in SURMOUNT-1 Trial

Biosimilar Insulins 2026: Access and Interchangeability Guidelines for Lantus and Basaglar

Verified HCP Portal